A few years later, the HDAC inhibitor was tested as monotherapy for recurrent GBM in a Phase II clinical trial (21), and in combination with TMZ and radiation therapy for newly diagnosed GBM in a Phase I/II clinical trial (22). This evidence concerns the gene HDAC9 and glioblastoma.